Tested Applications
| Positive IHC detected in | human tonsillitis tissue,  human lymphoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 | 
Recommended dilution
| Application | Dilution | 
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:100-1:400 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| IHC | See 2 publications below | 
| IF | See 1 publications below | 
Product Information
22351-1-AP targets CCR3 in IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human | 
| Cited Reactivity | human, mouse | 
| Host / Isotype | Rabbit / IgG | 
| Class | Polyclonal | 
| Type | Antibody | 
| Immunogen | CatNo: Ag17926 Product name: Recombinant human CCR3 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 310-354 aa of BC110297 Sequence: KYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVPredict reactive species | 
| Full Name | chemokine (C-C motif) receptor 3 | 
| Calculated Molecular Weight | 355 aa, 41 kDa | 
| GenBank Accession Number | BC110297 | 
| Gene Symbol | CCR3 | 
| Gene ID (NCBI) | 1232 | 
| RRID | AB_2879085 | 
| Conjugate | Unconjugated | 
| Form | Liquid | 
| Purification Method | Antigen Affinity purified | 
| UNIPROT ID | P51677 | 
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. | 
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. | 
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for CCR3 antibody 22351-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| Int Immunopharmacol Emu oil alleviates atopic dermatitis-like responses by inhibiting Cdc42 signaling of keratinocyte | ||
| Theranostics CD34+ PI16+ fibroblast progenitors aggravate neointimal lesions of allograft arteries via CCL11/CCR3-PI3K/AKT pathway | ||
| Oncol Rep SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy | 












